253 related articles for article (PubMed ID: 19877725)
1. Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.
Henney HR; Chez M
Paediatr Drugs; 2009; 11(6):397-406. PubMed ID: 19877725
[TBL] [Abstract][Full Text] [Related]
2. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
3. Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase.
Star K; Norén GN; Nordin K; Edwards IR
Drug Saf; 2011 May; 34(5):415-28. PubMed ID: 21513364
[TBL] [Abstract][Full Text] [Related]
4. Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database.
Rudolph A; Dahmke H; Kupferschmidt H; Burden A; Weiler S
Eur J Clin Pharmacol; 2021 Jun; 77(6):895-902. PubMed ID: 33404754
[TBL] [Abstract][Full Text] [Related]
5. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
Vakhapova V; Auriel E; Karni A
Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
Henney HR; Fitzpatrick A; Stewart J; Runyan JD
Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
[TBL] [Abstract][Full Text] [Related]
7. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
8. Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials.
Qu H; Wu J; Ma C; Qiaolongbatu X; Song X; Feng T; Wu Z; Lou Y; Fan G
Clin Pharmacol Ther; 2023 Jul; 114(1):201-210. PubMed ID: 37087633
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
10. [Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia].
Tanaka H; Fukuda I; Miyamoto A; Oka R; Cho K; Fujieda K
No To Hattatsu; 2004 Nov; 36(6):455-60. PubMed ID: 15560387
[TBL] [Abstract][Full Text] [Related]
11. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
Johnson TR; Tobias JD
J Child Neurol; 2000 Dec; 15(12):818-9. PubMed ID: 11198499
[TBL] [Abstract][Full Text] [Related]
12. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
14. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Kamen L; Henney HR; Runyan JD
Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database.
Carnovale C; Mahzar F; Scibelli S; Gentili M; Arzenton E; Moretti U; Leoni O; Pozzi M; Peeters GGAM; Clementi E; Medaglia M; Radice S
Eur J Pediatr; 2019 Feb; 178(2):161-172. PubMed ID: 30374752
[TBL] [Abstract][Full Text] [Related]
16. Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review.
Killam-Worrall L; Brand R; Castro JR; Patel DS; Huynh K; Lindley B; Torres BP
Ann Pharmacother; 2024 May; 58(5):523-532. PubMed ID: 37589096
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
[TBL] [Abstract][Full Text] [Related]
18. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
19. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
20. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
